Nav: Home

CRISPR screen reveals new targets in more than half of all squamous cell carcinomas

September 18, 2018

A little p63 goes a long way in embryonic development - and flaws in p63 can result in birth defects like cleft palette, fused fingers or even missing limbs. But once this early work is done, p63 goes silent, sitting quietly in the genome from that point forward. Unless it is accidentally reactivated. When p63 comes back to life within the adult genome, the result can be cancer. More than half of all squamous cell carcinomas, often found in the skin, lung, breast, and head/neck, involve excess p63 activity.

Researchers have known that p63 drives squamous cell cancers. The question has been what to do about it. Unfortunately, it has been impossible to simply switch off p63. And so the question becomes how else can doctors and researchers interfere with the action of p63 to shield patients from its cancerous effects.

Today, a team of University of Colorado Cancer Center researchers working in the lab of Joaquin Espinosa, PhD, sheds light on p63 activity in squamous cell carcinoma of the lung, providing an actionable path forward to drug development against this known cause of cancer. The study is published in the journal Cell Reports.

"The question that initiates this study is what is this oncogene, p63, doing to drive cell proliferation and why too much of it would cause cancer," Espinosa says.

To answer this question, Espinosa and colleagues including first author Christopher Abraham, PhD, used the CU Cancer Center Functional Genomics Shared Resource to run cells through a genome-wide CRISPR screen - a cutting-edge technology that enables the analysis of thousands of genes in a single experiment. The group started with lung squamous cell carcinoma cells that require the oncogenic product of the p63 gene, namely a protein called Np63a, in order to proliferate. Then the group turned off the production Np63a in these cells.

Of course, at that point, these cancer cells that needed Np63a stopped proliferating. Espinosa and colleagues hypothesized that Np63a had been suppressing the action of key tumor-suppressor genes (turning off the genes that turn off cancer), and now without Np63a these key anti-proliferative genes were again allowed to take over and stop cell division.

"It's an example of the classic tug-of-war between oncogenes and tumor-suppressor genes - based on this balance, you either have cancer or you don't," Espinosa says.

In order to identify these tumor suppressor genes playing a tug-of-war with Np63a, the group used the CRISPR screen to turn off thousands of genes across the genome to discover which genes, when inactivated, would allow these cancer cells to restart their growth (and thus, which genes ΔNp63α suppresses to aid the growth of cancer).

"We screened the entire genome and there was one molecular pathway, super clean and super clear, that Np63a needed to turn off to drive the growth of squamous cell carcinoma cells," Espinosa says.

The key tumor suppressor genes in this pathway are TGFB2 and RHOA.

When the group looked in the Cancer Genome Atlas at published data of 518 samples of lung squamous cell carcinoma, they found that in cancers with activated Np63a, about 80 percent also showed inactivated TGFB2 and RHOA.

"Np63a shuts off TGFB2 and RHOA to promote cancer progression, and this is clearly a widespread phenomenon in squamous cell carcinomas," Espinosa says.

The path to a therapy against Np63a seems clear: activate TGFB2 and RHOA.

"If there was a way to deliver something that mimics TGFB2, perhaps we could stop proliferation of squamous cell carcinoma," Espinosa says.

Or, RHOA is an enzyme that can switch between active and inactive forms.

"So if you can find drugs that lock RHOA in its active form, that would shut down cell proliferation, as well," Espinosa says.

"This is a potentially druggable pathway that is driving the progression of squamous cell carcinomas," Espinosa says. "The challenge now is to exploit this knowledge for therapeutics, to find a way to reactivate the TGFB/RHOA pathway to save the lives of patients with cancers."
-end-


University of Colorado Anschutz Medical Campus

Related Cancer Articles:

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.
Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.
Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
More Cancer News and Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Sound And Silence
Sound surrounds us, from cacophony even to silence. But depending on how we hear, the world can be a different auditory experience for each of us. This hour, TED speakers explore the science of sound. Guests on the show include NPR All Things Considered host Mary Louise Kelly, neuroscientist Jim Hudspeth, writer Rebecca Knill, and sound designer Dallas Taylor.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

Kittens Kick The Giggly Blue Robot All Summer
With the recent passing of Ruth Bader Ginsburg, there's been a lot of debate about how much power the Supreme Court should really have. We think of the Supreme Court justices as all-powerful beings, issuing momentous rulings from on high. But they haven't always been so, you know, supreme. On this episode, we go all the way back to the case that, in a lot of ways, started it all.  Support Radiolab by becoming a member today at Radiolab.org/donate.